Illumina, Inc. (NASDAQ:ILMN) – Leerink Swann issued their Q1 2019 earnings estimates for Illumina in a report released on Wednesday, according to Zacks Investment Research. Leerink Swann analyst P. Souda anticipates that the life sciences company will post earnings per share of $1.28 for the quarter. Leerink Swann currently has a “Outperform” rating and a $225.00 price objective on the stock. Leerink Swann also issued estimates for Illumina’s Q2 2019 earnings at $1.31 EPS.
Several other equities research analysts have also recently commented on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a research report on Monday, October 9th. Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Citigroup Inc. boosted their price target on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 25th. Bank of America Corporation boosted their price target on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $217.50 price target on the stock in a research report on Tuesday, September 19th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $200.88.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/leerink-swann-comments-on-illumina-inc-s-q1-2019-earnings-ilmn.html.
Shares of Illumina (NASDAQ ILMN) opened at $208.94 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 1-year low of $119.37 and a 1-year high of $214.50. The firm has a market cap of $30,505.24, a PE ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.97 earnings per share.
In related news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $194.73, for a total value of $3,894,600.00. Following the completion of the sale, the director now owns 539,176 shares of the company’s stock, valued at approximately $104,993,742.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total value of $29,827.95. The disclosure for this sale can be found here. In the last three months, insiders sold 187,964 shares of company stock valued at $38,454,069. 1.60% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC boosted its position in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the period. Penserra Capital Management LLC boosted its position in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the period. Dupont Capital Management Corp bought a new stake in Illumina during the third quarter worth approximately $153,000. Paradigm Asset Management Co. LLC boosted its position in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the period. Finally, Patten Group Inc. boosted its position in Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the period. 93.07% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Get a free copy of the Zacks research report on Illumina (ILMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.